HawkInsight

  • Contact Us
  • App
  • English

BioNTech U.S. Stocks Fall Nearly 3% Before Market, Pfizer Up 0.5%。Pfizer and BioNTech's Phase 3 Clinical Trial of the mRNA-Based Influenza and Covid Vaccine Project Fails to Meet One of the Key Goals。

BioNTech U.S. Stocks Fall Nearly 3% Before Market, Pfizer Up 0.5%。Pfizer and BioNTech's Phase 3 Clinical Trial of the mRNA-Based Influenza and Covid Vaccine Project Fails to Meet One of the Key Goals。

Disclaimer: The views in this article are from the original author and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.

NewFlashHawk Insight
More